244 related articles for article (PubMed ID: 17299510)
21. The effects of neuropsychiatric drugs on glycogen synthase kinase-3 signaling.
Sutton LP; Rushlow WJ
Neuroscience; 2011 Dec; 199():116-24. PubMed ID: 22001305
[TBL] [Abstract][Full Text] [Related]
22. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus.
Kaidanovich-Beilin O; Milman A; Weizman A; Pick CG; Eldar-Finkelman H
Biol Psychiatry; 2004 Apr; 55(8):781-4. PubMed ID: 15050857
[TBL] [Abstract][Full Text] [Related]
23. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.
Engel T; Goñi-Oliver P; Lucas JJ; Avila J; Hernández F
J Neurochem; 2006 Dec; 99(6):1445-55. PubMed ID: 17059563
[TBL] [Abstract][Full Text] [Related]
24. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania.
Prickaerts J; Moechars D; Cryns K; Lenaerts I; van Craenendonck H; Goris I; Daneels G; Bouwknecht JA; Steckler T
J Neurosci; 2006 Aug; 26(35):9022-9. PubMed ID: 16943560
[TBL] [Abstract][Full Text] [Related]
25. β-catenin promoter ChIP-chip reveals potential schizophrenia and bipolar disorder gene network.
Pedrosa E; Shah A; Tenore C; Capogna M; Villa C; Guo X; Zheng D; Lachman HM
J Neurogenet; 2010 Dec; 24(4):182-93. PubMed ID: 20615089
[TBL] [Abstract][Full Text] [Related]
26. Examination of methylphenidate-mediated behavior regulation by glycogen synthase kinase-3 in mice.
Mines MA; Beurel E; Jope RS
Eur J Pharmacol; 2013 Jan; 698(1-3):252-8. PubMed ID: 23099259
[TBL] [Abstract][Full Text] [Related]
27. GSK-3 activity in neocortical cells is inhibited by lithium but not carbamazepine or valproic acid.
Jonathan Ryves W; Dalton EC; Harwood AJ; Williams RS
Bipolar Disord; 2005 Jun; 7(3):260-5. PubMed ID: 15898963
[TBL] [Abstract][Full Text] [Related]
28. Tau overexpression in transgenic mice induces glycogen synthase kinase 3beta and beta-catenin phosphorylation.
Shim SB; Lim HJ; Chae KR; Kim CK; Hwang DY; Jee SW; Lee SH; Sin JS; Leem YH; Lee SH; Cho JS; Lee HH; Choi SY; Kim YK
Neuroscience; 2007 May; 146(2):730-40. PubMed ID: 17337327
[TBL] [Abstract][Full Text] [Related]
29. The effect of citalopram on chronic stress-induced depressive-like behavior in rats through GSK3β/β-catenin activation in the medial prefrontal cortex.
Chen YC; Tan QR; Dang W; Wang HN; Zhang RB; Li ZY; Lin H; Liu R
Brain Res Bull; 2012 Jul; 88(4):338-44. PubMed ID: 22472057
[TBL] [Abstract][Full Text] [Related]
30. Glycogen synthase kinase 3beta as a likely target for the action of lithium on circadian clocks.
Padiath QS; Paranjpe D; Jain S; Sharma VK
Chronobiol Int; 2004 Jan; 21(1):43-55. PubMed ID: 15129823
[TBL] [Abstract][Full Text] [Related]
31. Lithium- and valproate-induced alterations in circadian locomotor behavior in Drosophila.
Dokucu ME; Yu L; Taghert PH
Neuropsychopharmacology; 2005 Dec; 30(12):2216-24. PubMed ID: 15956996
[TBL] [Abstract][Full Text] [Related]
32. The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature.
Costemale-Lacoste JF; Guilloux JP; Gaillard R
Encephale; 2016 Apr; 42(2):156-64. PubMed ID: 26995153
[TBL] [Abstract][Full Text] [Related]
33. Lithium and tamoxifen modulate cellular plasticity cascades in animal model of mania.
Cechinel-Recco K; Valvassori SS; Varela RB; Resende WR; Arent CO; Vitto MF; Luz G; de Souza CT; Quevedo J
J Psychopharmacol; 2012 Dec; 26(12):1594-604. PubMed ID: 23076832
[TBL] [Abstract][Full Text] [Related]
34. Antipsychotic-like effects of a neurotensin receptor type 1 agonist.
Vadnie CA; Ayers-Ringler J; Oliveros A; Abulseoud OA; Choi S; Hitschfeld MJ; Choi DS
Behav Brain Res; 2016 May; 305():8-17. PubMed ID: 26909848
[TBL] [Abstract][Full Text] [Related]
35. Questioning the predictive validity of the amphetamine-induced hyperactivity model for screening mood stabilizing drugs.
Lan A; Einat H
Behav Brain Res; 2019 Apr; 362():109-113. PubMed ID: 30630015
[TBL] [Abstract][Full Text] [Related]
36. A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors.
Du J; Wei Y; Liu L; Wang Y; Khairova R; Blumenthal R; Tragon T; Hunsberger JG; Machado-Vieira R; Drevets W; Wang YT; Manji HK
Proc Natl Acad Sci U S A; 2010 Jun; 107(25):11573-8. PubMed ID: 20534517
[TBL] [Abstract][Full Text] [Related]
37. Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing.
Su Y; Ryder J; Li B; Wu X; Fox N; Solenberg P; Brune K; Paul S; Zhou Y; Liu F; Ni B
Biochemistry; 2004 Jun; 43(22):6899-908. PubMed ID: 15170327
[TBL] [Abstract][Full Text] [Related]
38. Sustained behavioral effects of lithium exposure during early development in zebrafish: involvement of the Wnt-β-catenin signaling pathway.
Nery LR; Eltz NS; Martins L; Guerim LD; Pereira TC; Bogo MR; Vianna MR
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Dec; 55():101-8. PubMed ID: 24813569
[TBL] [Abstract][Full Text] [Related]
39. High lithium levels in tobacco may account for reduced incidences of both Parkinson's disease and melanoma in smokers through enhanced β-catenin-mediated activity.
Guttuso T
Med Hypotheses; 2019 Oct; 131():109302. PubMed ID: 31443765
[TBL] [Abstract][Full Text] [Related]
40. Mice with neuron-specific accumulation of mitochondrial DNA mutations show mood disorder-like phenotypes.
Kasahara T; Kubota M; Miyauchi T; Noda Y; Mouri A; Nabeshima T; Kato T
Mol Psychiatry; 2006 Jun; 11(6):577-93, 523. PubMed ID: 16619054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
